Results 261 to 270 of about 151,903 (303)

Perillaldehyde Attenuates Diabetic Nephropathy through Modulation of the Nrf2/Keap1 and NF-κB Signalling Pathways. [PDF]

Cell Biol Int
Ramachandran H, Mourya AK, Kumar A.
europepmc   +1 more source

TXNIP Is Positioned as a Key Mediator of Hyperglycemia-Induced Vascular Senescence. [PDF]

Diabetes
Qian X, Chen X, Chai Y, Niu Y, Ning X, Mao Q, Hu Q, Su Q.   +7 more
europepmc   +1 more source

The Senescent Phenotype of Cultured Hypothalamic Astrocytes from Rats with Streptozotocin-Induced Dementia. [PDF]

Neurochem Res
Da Silva VF, da Costa DS, Gayger-Dias V, Sobottka TM, Da Silva ACR, Biolchi BCR, da Silva LF, Zasso N, Weber FB, Schimitz I, Machado DN, Netto CA, Leite MC, Bobermin LD, Quincozes-Santos A, Gonçalves CA.   +15 more
europepmc   +1 more source

Transcriptomic Profiling of Diabetic Porcine Wound Healing Model Identifies Key Metabolic, Inflammatory, and Oxidative Stress Pathways. [PDF]

Wound Repair Regen
McCune JT, Bezold MG, Davidson JM, Serezani CH, Cook RS, Duvall CL.   +5 more
europepmc   +1 more source

Voluntary wheel running in male mice mitigates select hyperglycemia-induced depressive-like behaviors and modulates BDNF and <i>Tnf</i> in a brain region-specific manner. [PDF]

Brain Behav Immun Health
Kusumo LE, Reese GA, Folh MJ, Duhon JP, Bonner RL, Read GM, Fowler CG, Vichaya EG.   +7 more
europepmc   +1 more source

Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

Neuroendocrinology, 2022
In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date.
J. Capdevila, M. Ducreux, Rocio García Carbonero, E. Grande, T. Halfdanarson, M. Pavel, S. Tafuto, S. Welin, V. Valentí, R. Salazar   +9 more
semanticscholar   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Streptozotocin as a tool for induction of rat models of diabetes: a practical guide

EXCLI Journal : Experimental and Clinical Sciences, 2023
Streptozotocin (STZ) is the most used diabetogenic chemical for creating rat models of type 1 and type 2 diabetes. Despite ~60 years of using STZ in animal diabetes research, some prevailing views about STZ preparation and use are not supported by ...
A. Ghasemi, S. Jeddi
semanticscholar   +1 more source

Challenges and issues with streptozotocin-induced diabetes - A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics.

Chemico-Biological Interactions, 2016
Streptozotocin (STZ) has been extensively used over the last three decades to induce diabetes in various animal species and to help screen for hypoglycemic drugs.
Sameer N. Goyal, N. M. Reddy, K. Patil, K. T. Nakhate, S. Ojha, Chandragouda R. Patil, Yogeeta O. Agrawal   +6 more
semanticscholar   +1 more source

Hesperidin, a citrus flavonoid ameliorates hyperglycemia by regulating key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats

Toxicology Mechanisms and Methods, 2019
The present study investigated the protective effect of hesperidin on carbohydrate metabolizing enzymes in streptozotocin-induced diabetic rats. Hesperidin was administered to streptozotocin-induced (40 mg/kg b.w.) diabetic rats at different dosages of ...
R. Sundaram, E. Nandhakumar, H. Banu
semanticscholar   +1 more source